Honoring our roots, caring for our community.

Investigational · not currently FDA-approved

Ipamorelin + Sermorelin: what the evidence shows

Educational information about two growth-hormone secretagogues, their limits, their risks and their regulatory status.

Evidence-based care Individualized plan
Ipamorelin + Sermorelin

Introduction

An investigational combination, explained clearly

Ipamorelin and sermorelin are two synthetic peptides that act on the pituitary gland, which controls the release of growth hormone. Some compounding pharmacies prepare them together.

This page explains what is known and what is not. The combination is not an FDA-approved product, and its benefits have not been established in people. Any decision starts with a medical evaluation.

Overview

What are ipamorelin and sermorelin?

Sermorelin is a synthetic form of part of growth hormone-releasing hormone (GHRH), the signal the brain uses to tell the pituitary gland to release growth hormone.

Ipamorelin is a synthetic peptide that acts on a different receptor, the ghrelin (growth hormone secretagogue) receptor, which can also trigger growth hormone release. The two act through different pathways, which is the theoretical reason they are combined; the combination itself has not been studied in clinical trials.

Mechanisms

Proposed mechanisms and available evidence

Sermorelin

Stimulates the GHRH receptor in the pituitary. It was once approved for children with growth hormone deficiency; studies in adults are small and limited.

Ipamorelin

Activates the ghrelin receptor and raised growth hormone in early studies. It has never been approved, and human data are limited.

Research

What is being studied

Growth hormone secretagogues have been studied for age-related changes in growth hormone, body composition and recovery. In healthy adults, results are inconsistent, and raising growth hormone or IGF-1 levels has not been shown to improve health, strength or longevity.

Next step

Talk with a provider first

If you are concerned about energy, body composition or hormones, a medical evaluation helps identify proven options.

Request a medical consultation

Limitations

Clinical limitations

Not an approved combination

No FDA-approved product contains both peptides.

No long-term safety data

Effects of use over months or years are unknown.

Higher levels are not proof of benefit

A rise in growth hormone does not mean better health.

Product quality varies

Compounded products are not reviewed like approved drugs.

Risks

Possible risks and side effects

Seek urgent care for signs of a severe allergic reaction, such as swelling or difficulty breathing.

Injection-site reactions

Redness, swelling or itching.

Headache or flushing

Usually temporary.

Fluid retention or joint discomfort

Reported with growth hormone effects.

Changes in blood sugar

Growth hormone can reduce insulin sensitivity.

Unknown long-term effects

Including effects of sustained higher IGF-1.

Allergic reactions

Uncommon but possible.

Safety

Contraindications and precautions

These peptides may not be appropriate if any of the following apply to you:

  • Pregnancy or breastfeeding (consult your provider)
  • Active cancer or a history of cancer
  • Uncontrolled diabetes or significant chronic illness
  • Pituitary or endocrine disorders
  • Children and adolescents under 18
  • Competitive athletes subject to anti-doping testing — Growth hormone secretagogues are prohibited in sport.

Evaluation

Medical evaluation

01

History and goals

Your symptoms, conditions, medications and expectations.

02

Laboratory tests, as indicated

Such as IGF-1 or blood sugar, to look for a cause.

03

Approved alternatives

Diagnosed conditions are treated with approved options.

Follow-up

Follow-up when appropriate

If a provider prescribes any treatment, follow-up is individualized.

Symptoms and side effects

Reviewed at each visit.

Blood sugar

Checked when indicated.

IGF-1, when indicated

To avoid levels that are too high.

Need to continue

Treatment is stopped if there is no clear benefit.

Regulatory status

Regulatory status

Sermorelin was once FDA-approved for children with growth hormone deficiency; the manufacturer stopped producing it in 2008 for reasons not related to safety, and no approved sermorelin product is currently marketed in the U.S.

Ipamorelin has never been FDA-approved, and the FDA has identified safety concerns about its use in compounded drugs. The ipamorelin + sermorelin combination is not an FDA-approved product. Growth hormone secretagogues are prohibited in competitive sport.

FAQ

Ipamorelin + Sermorelin FAQs

Clear answers to help you prepare.

No. The combination is not an FDA-approved product. Sermorelin was approved in the past for children with growth hormone deficiency, but that product is no longer marketed, and ipamorelin has never been approved.

These effects have not been established in clinical studies of this combination. Your provider can discuss proven options for your goals.

No. Raising growth hormone has not been shown to slow aging or extend life, and long-term safety is unknown.

Growth hormone secretagogues are prohibited in competitive sport, including out of competition.

Any medicine, dose, route and schedule are decided only by a licensed provider after an individual evaluation. This page is educational and does not give treatment instructions.

Information on this page is educational and does not replace medical evaluation. Treatment options are determined individually.